(Press-News.org) For decades, researchers have worked to develop therapies that can prime the immune system to recognize and attack proteins on the surface of tumor cells. However, success has been limited due to the technological challenge of engineering therapies that provide specific enough “training” to the immune system to identify a given patient’s neoantigens. Now, investigators from Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, have evaluated an investigational, individualized neoantigen therapy (INT), containing patient-specific mRNA-encoded instructions that the immune system can use to target cancer-causing cells. Their results highlight the safety, feasibility, and therapeutic promise of the approach, which has been designated breakthrough status by the U.S. Food and Drug Administration (FDA) to accelerate further clinical research. The study was published in Cancer Discovery, a journal of the American Association for Cancer Research.
“We are entering an era in which we have the tools to make cancer therapies more precise and more personalized,” said corresponding author Justin Gainor, MD, program director of the Center for Thoracic Cancers at MGH. “While it may sound like science fiction, we’ve shown that we can develop an individualized neoantigen therapy by leveraging the specific characteristics of a given patient’s tumor and cell-type. This therapy was both safe and immunogenic, meaning that we were able to amplify existing responses and induce brand new, long-lasting immune responses.”
The Phase 1 study (NCT03313778), sponsored by Moderna, Inc., in collaboration with Merck, known as MSD outside of the United States and Canada, evaluated a novel INT called mRNA-4157 (V940). The trial included 16 patients, four with resected non-small cell lung cancer and 12 with resected cutaneous melanoma. The researchers performed comprehensive genomic sequencing of each patient’s tumor to determine their top neoantigens, up to 34 of which were then encoded in each mRNA therapy. Therapies and vaccines that use mRNA can produce robust immune responses and are optimal for individualized cancer therapies because the mRNA corresponding to the patient’s neoantigens can easily be inserted into the therapy’s delivery system.
Ultimately, 12 patients completed the study: two patients were lost to follow-up, one discontinued due to an adverse event not associated with mRNA-4157 (V940) treatment, and one died of unspecified causes over a year after completing treatment. Treatment with mRNA-4157 (V940) was not associated with dose-limiting toxicity, study discontinuation, or high-grade adverse events in any patients. The most common side effects included low-grade fatigue, fever and tenderness around the injection site.
In this study, patients with melanoma were treated with both mRNA-4157 (V940) and pembrolizumab, an immune checkpoint inhibitor that boosts anti-cancer activity. Such immunotherapies have become increasingly important in treating cancer and may be used alongside INTs to further increase the immune system’s ability to stage a long-lasting response to cancer. The low toxicity profile of mRNA-4157 (V940) is especially important as it could help simplify combining INTs and other immunotherapies.
The researchers’ analysis of patients with blood testing both pre- and post-treatment showed that mRNA-4157 (V940) induced multiple forms of T cell proliferation, both alone and in conjunction with pembrolizumab. Importantly, the T cell response to neoantigens was sustained 30 weeks after treatment, testifying to the potential long-term impact of the therapy. The FDA granted a breakthrough therapy designation to the study of mRNA-4157 (V940) with pembrolizumab for melanoma treatment, which can help expedite the development and review of the treatment. The researchers are also seeking to further advance the study of the INT in non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, and cutaneous squamous cell carcinoma.
“The excitement around immune therapies, including this one, is their potential for durability,” Gainor said. “We showed that this INT was able to generate new immune responses against neoantigens, and it appeared that those immune responses were maintained at later time points. The potential for a precise, durable immune response is one of the most exciting aspects of therapies like this one. This may enable a new treatment paradigm for oncology care, particularly in the adjuvant setting.”
Paper cited: Gainor, JF et al. “T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603 Study” Cancer Discovery DOI: http://doi.org/10.1158/2159-8290.CD-24-0158
###
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org
END
WASHINGTON—Women with the common reproductive and metabolic condition polycystic ovary syndrome (PCOS) face a greater risk of developing bulimia, binge eating disorder and disordered eating, according to new research published in The Journal of Clinical Endocrinology & Metabolism.
PCOS affects roughly one in eight women. Women who have the condition face an increased risk of developing metabolic problems such as diabetes, reproductive issues such as infertility, and psychological issues including anxiety and depression.
Women are diagnosed when they have at least two of the three ...
A Korean research team has presented the first universal design principles for solid-state batteries, signaling a paradigm shift in battery design research that previously lacked standard benchmarks.
Dr. Jinsoo Kim from the Ulsan Advanced Energy Technology R&D Center of the Korea Institute of Energy Research (KIER) and Professor Sung-Kyun Jung's research team from the Ulsan National Institute of Science and Technology (UNIST) have jointly developed a design principles and a versatile design toolkit for implementing high-energy-density solid-state batteries and have completed performance verification.
With ...
Nationally, falls remain the leading cause of both fatal and non-fatal injuries in older adults and are the leading cause of traumatic brain injury. In 2021, falls led to the deaths of 36,500 older adults in the United States and 3,805 older Floridians. While some studies have hypothesized that alcohol use contributed to these outcomes, there are few studies which have examined this issue.
As such, little is known about the association between the frequency of alcohol use and the severity of injuries sustained after a fall in older adults. A study by Florida Atlantic University’s Schmidt College of Medicine and collaborators, is one of the first to examine the relationship ...
CAMBRIDGE, Mass., Aug 8, 2024 --- Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced ISM6331, potential best-in-class pan-TEAD inhibitor, has received the U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for the treatment of mesothelioma, following the grant of Orphan Drug Designation (ODD) in June 2024. It brings the total number of IND-approved molecules of Insilico to nine.
Mesothelioma is a type of cancer that affects the mesothelium, a thin layer of tissue that covers most of the ...
A crowd or a flock of birds have different characteristics from those of atoms in a material, but when it comes to collective movement, the differences matter less than we might think. We can try to predict the behavior of humans, birds, or cells based on the same principles we use for particles. This is the finding of a new study published in the Journal of Statistical Mechanics: Theory and Experiment, JSTAT, conducted by an international team that includes the collaboration of MIT in Boston and CNRS in France. The study, based on the physics ...
Experts provide clarity on key terms for urgent species recovery actions to support the implementation of the Global Biodiversity Framework.
The Kunming-Montreal Global Biodiversity Framework (KMGBF) is a landmark agreement ratified in 2022 by Parties to the Convention on Biological Diversity that outlines ambitious goals to combat biodiversity decline.
The Framework states outcomes for species to be achieved by 2050 in Goal A and establishes a range of targets to reduce pressures on biodiversity and halt biodiversity loss ...
As our climate changes and soil salinity increases in many agricultural areas, finding crops that can thrive in these challenging conditions is crucial. Cultivated tomatoes, while delicious, often struggle in salty soils. Their wild cousins, however, have evolved to survive in diverse and often harsh environments. A recent study delved into the genetic treasure trove of wild tomatoes to uncover secrets of salt tolerance that could be used to develop resilient crop varieties.
A team of researchers focused on Solanum pimpinellifolium, the closest wild relative of our beloved cultivated tomato. These tiny, ...
Climate change is one of the most significant environmental challenges of present times, leading to extreme weather events, including droughts, forest fires, and floods. The primary driver for climate change is the release of greenhouse gases into the atmosphere due to human activities, which trap heat and raise Earth’s temperature. Aerosols (such as particulate matter, PM2.5) not only affect public health but also influence the Earth's climate by absorbing and scattering sunlight and altering cloud properties. Although future climate change predictions are being reported, it is possible that the impacts of climate change could be more severe than predicted. ...
According to the attention-based view, a firm’s actions and growth performance are directly influenced by its attentional allocation to specific issues. The consequences of organizational attention are reflected in the firm’s strategic decision-making and adaptability. However, existing literature is limited in its exploration of how a firm’s attentional uniqueness impacts its behavior and performance. Notably, attentional uniqueness refers to how the firm’s attentional allocation diverges from competitors in the same industry.
To address the above-mentioned knowledge gap, Associate Professor Takumi ...
The deoxyribonucleic acid or DNA, the molecular system that carries the genetic information of living organisms, can transcribe and amplify information using its two helical strands. Creating such artificial molecular systems that match or surpass DNA in functionality is of great interest to scientists. Double-helical foldamers are one such molecular system.
Helical foldamers are a class of artificial molecules that fold into well-defined helical structures like helices found in proteins and nucleic acids. They have garnered considerable attention as stimuli-responsive switchable molecules, tuneable chiral materials, and cooperative supramolecular systems due to their chiral and ...
